Table 1.
Demographic characteristics of the study subjects.
| ECT group | Control group | |||||
|---|---|---|---|---|---|---|
| Mean | Count | N (%) | Mean | Count | N (%) | |
| Age | 48.8 | 55.6 | ||||
| Gender | ||||||
| Male | 11 | 55.0 | 8 | 40.0 | ||
| Female | 9 | 45.0 | 12 | 60.0 | ||
| Diagnosis | ||||||
| Major depression,* recurrent | 12 | 60.0 | 12 | 60.0 | ||
| Major depression * single episode | 0 | 0.0 | 5 | 25.0 | ||
| Bipolar disorder, currently in a depressive episode* | 6 | 30.0 | 1 | 5.0 | ||
| Schizoaffective disorder | 2 | 10.0 | 2 | 10.0 | ||
| Medication | ||||||
| Tricyclic antidepressants | ||||||
| No | 16 | 80.0 | 17 | 85.0 | ||
| Yes | 4 | 20.0 | 3 | 15.0 | ||
| SSR1 | ||||||
| No | 13 | 65.0 | 13 | 65.0 | ||
| Yes | 7 | 35.0 | 7 | 35.0 | ||
| SNRI | ||||||
| No | 16 | 80.0 | 12 | 60.0 | ||
| Yes | 4 | 20.0 | 8 | 40.0 | ||
| MAO inhibitors | ||||||
| No | 18 | 90.0 | 20 | 100.0 | ||
| Yes | 2 | 10.0 | 0 | 0.0 | ||
| Typical antipsychotics | ||||||
| No | 16 | 84.2 | 18 | 90.0 | ||
| Yes | 3 | 15.8 | 2 | 10.0 | ||
| Atypical antipsychotics | ||||||
| No | 5 | 25.0 | 9 | 45.0 | ||
| Yes | 15 | 75.0 | 11 | 55.0 | ||
| Betablocker | ||||||
| No | 15 | 75.0 | 16 | 80.0 | ||
| Yes | 5 | 25.0 | 4 | 20.0 | ||
| L-thyroxine | ||||||
| No | 15 | 75.0 | 14 | 70.0 | ||
| Yes | 5 | 25.0 | 6 | 30.0 | ||
| Mirtazapine | ||||||
| No | 17 | 85.0 | 14 | 70.0 | ||
| Yes | 3 | 15.0 | 6 | 30.0 | ||
| Lithium | ||||||
| No | 18 | 90.0 | 15 | 75.0 | ||
| Yes | 2 | 10.0 | 5 | 25.0 | ||
| Benzodiazepines | ||||||
| No | 15 | 75.0 | 14 | 70.0 | ||
| Yes | 5 | 25.0 | 6 | 30.0 | ||
| Antiepileptics | ||||||
| No | 16 | 80.0 | 15 | 75.0 | ||
| Yes | 4 | 20.0 | 5 | 25.0 | ||
*A11 probands fulfilled the criteria of a moderate depressive episode (BDI: 20-28 points).